Prana Biotechnology Limited, a development stage company, is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain and the eye as the aging process progresses. Platform Technology and Research Programs The company’s platform technology addresses the causes of a spectrum of neurodegenerative and age-related diseases based on the interrelationship of metals and proteins. Its research efforts have been directed at research into potential therapeutics for the treatment of Alzheimer’s disease, Huntington’s disease, and Parkinson’s disease. The company’s platform technology might also be applicable for certain cancers; age-related macular degeneration; Motor Neuron disease; Creutzfeldt-Jakob disease; age-related cataracts; and other neurodegenerative diseases. The company has initiated a program of research into the potential use of selected metal protein attenuating compounds from its library for use in the treatment of brain cancer, in particular the prevalent and deadly form of the disease, Glioblastoma Multiforme. Its scientists have developed a pipeline of compounds across multiple chemical classes that target the interaction of specific metals and certain aggregating proteins, such as beta-amyloid. PBT2, the company’s Alzheimer’s and Huntington’s disease lead metal protein attenuating compound product candidate and PBT434, its candidate lead compound for Parkinson’s disease and movement disorders are selected from the ‘rationally designed’ pipeline. Regulatory Considerations The company’s ongoing research and development activities are subject to regulation by human research ethics committees and institutional research boards, as well as various governmental authorities in Australia, principally the Therapeutics Goods Administration, the Food and Drug Administration in the United States, the Medicines and Healthcare products Regulatory Agency in the United Kingdom, and the European Medicines Agency. History Prana Biotechnology Limited was founded in 1997. The company was incorporated under the laws of the Commonwealth of Australia in 1997.
prana biotechnology ltd-adr
(PRAN:Consolidated Issue listed on NASDAQ Capital Market)
369 Royal Parade
Parkville, VIC 3052
Phone: 61 3 9349 4906
Fax: 61 3 9348 0377www.pranabio.com
|No competitor information is available for PRAN.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact PRANA BIOTECHNOLOGY LTD-ADR, please visit www.pranabio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.